The "totality of evidence" and "extrapolation" of SB17, a ustekinumab biosimilar
{{output}}
Introduction: SB17 is a ustekinumab (UST) biosimilar targeting interleukin-12/23 for treating immune-medicated inflammatory diseases (IMIDs). The development of UST biosimilars like SB17 May help address the high cost of innovato... ...
